Kiniksa Pharmaceuticals International, plc
KNSA Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$76.73
KIRA · Stoqly’s AI analyst, in plain words
- Kiniksa Pharmaceuticals International, plc had $678M of revenue in fiscal 2025, up 60.1% on the year before.
- Its operating margin was 11.4%, up 22.2 pts: of every 100 in sales, about 11 is left after running the business.
- Kiniksa Pharmaceuticals International, plc made $59.0M of net profit in fiscal 2025.
- Free cash flow was $136M in fiscal 2025, 20.1% of revenue.
Market cap
$6.3B
P/E
84.3x
Revenue
$678M
Net income
$59.0M
Free cash flow
$136M
Operating margin
11.4%
Kiniksa Pharmaceuticals International, plc in 30 seconds · fiscal 2025
Are sales growing?
+60.1%
Yes. Sales grew 60.1% last year.
Does it make a profit?
8.7%
A little. It keeps 8.7% of every sale as profit.
Does profit turn into cash?
20.1%
Yes. 20.1% of sales ends up as free cash.
How healthy are the accounts?
7 / 8
Solid. It passes 7 of 8 health tests.
How is the share priced?
84.3x
One share costs 84.3 times its yearly profit per share.
What Kiniksa Pharmaceuticals International, plc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- Kiniksa Pharmaceuticals International, plc
- CIK
- 0001730430
Kiniksa Pharmaceuticals International, plc · KNSA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $38.5M | $220M | $270M | $423M | $678M |
| Revenue growth | — | 471.2% | 22.7% | 56.6% | 60.1% |
| Gross margin | 76.4% | 89.6% | 87.6% | 85.6% | 88.5% |
| Operating margin | −406.4% | 4.4% | −9.3% | −10.8% | 11.4% |
| Net income | −$158M | $183M | $14.1M | −$43.2M | $59.0M |
| Net margin | −409.7% | 83.3% | 5.2% | −10.2% | 8.7% |
| Diluted EPS | −$2.30 | $2.60 | $0.20 | −$0.60 | $0.75 |
| Cash | |||||
| Cash from operations | −$126M | $5.8M | $13.3M | $25.7M | $138M |
| Capital expenditure | $0.4M | $0.1M | $0.1M | $0.3M | $1.6M |
| Free cash flow | −$127M | $5.7M | $13.2M | $25.4M | $136M |
| FCF margin | −328.7% | 2.6% | 4.9% | 6.0% | 20.1% |
| Share count change | 10.9% | 2.7% | 2.1% | −0.7% | 10.6% |
| Debt and strength | |||||
| Cash and short-term investments | $182M | $191M | $206M | $244M | $414M |
| Shareholders' equity | $185M | $396M | $439M | $438M | $568M |
| Current ratio | 4.4x | 5.2x | 4.3x | 3.3x | 3.8x |
| Returns and quality | |||||
| Return on equity | −63.6% | 63.1% | 3.4% | −9.8% | 11.7% |
| Return on tangible equity | −95.3% | 48.5% | 3.3% | −10.2% | 10.7% |
| Piotroski F-score | — | 6 | 3 | 4 | 7 |
| Altman Z'' | −5.6 | 6.0 | 4.6 | 2.4 | 5.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$47.8M
8 insiders
Of sales under plans
99%
$47.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Kiniksa Pharmaceuticals International, plc · KNSA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $76.73 a share, the company is worth $6.3B: 84.3 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001730430). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.